G protein-coupled receptor 84Genealiases: EX33 · GPCR4
Q-omics provides the consensus-scored GPR84 profile across patient tissues and cancer cell-line models. GPR84 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GPR84 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GPR84 RNA expression shows 20,055 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where GPR84 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR84 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR84 survival associations across molecular data types. GPR84 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR84 RNA expression–survival associations across cancer types. High GPR84 expression shows unfavorable associations in KIRC, ACC and LGG, but favorable associations in SKCM, HNSC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GPR84 RNA expression.
This table summarizes GPR84 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GPR84. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR84 shows higher tumor expression in KIRC, HNSC, KIRP, THCA, COAD and LUAD. The KIRC box plot shows higher GPR84 RNA expression in tumor versus normal tissue (log2 FC = +1.135, t-test p < 0.001).
This table shows molecular features associated with GPR84 in patient tissues and cancer cell lines. In patient samples, GPR84 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR84 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
